Supernus Pharmaceuticals/$SUPN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Ticker
$SUPN
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
674
ISIN
US8684591089
Website
SUPN Metrics
BasicAdvanced
$1.8B
28.64
$1.11
0.74
-
Price and volume
Market cap
$1.8B
Beta
0.74
52-week high
$40.28
52-week low
$25.53
Average daily volume
430K
Financial strength
Current ratio
2.44
Quick ratio
2.162
Long term debt to equity
2.558
Total debt to equity
3.134
Management effectiveness
Return on assets (TTM)
2.76%
Return on equity (TTM)
6.32%
Valuation
Price to earnings (TTM)
28.637
Price to revenue (TTM)
2.627
Price to book
1.72
Price to tangible book (TTM)
4.31
Price to free cash flow (TTM)
10.745
Growth
Revenue change (TTM)
11.82%
Earnings per share change (TTM)
-464.25%
3-year revenue growth (CAGR)
3.57%
3-year earnings per share growth (CAGR)
-5.56%
What the Analysts think about SUPN
Analyst ratings (Buy, Hold, Sell) for Supernus Pharmaceuticals stock.
SUPN Financial Performance
Revenues and expenses
SUPN Earnings Performance
Company profitability
SUPN News
AllArticlesVideos
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
GlobeNewsWire·4 days ago
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·5 days ago
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals (SUPN) has a market cap of $1.8B as of June 02, 2025.
What is the P/E ratio for Supernus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Supernus Pharmaceuticals (SUPN) stock is 28.64 as of June 02, 2025.
Does Supernus Pharmaceuticals stock pay dividends?
No, Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders as of June 02, 2025.
When is the next Supernus Pharmaceuticals dividend payment date?
Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders.
What is the beta indicator for Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.